Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success” which provides an insight into the different endpoints that are used in cardiovascular clinical trials. The report examines various aspects of clinical trial endpoints in cardiovascular disorders, such as analysis of the major marketed cardiovascular drugs, with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, the most promising cardiovascular drugs in the therapeutic pipeline with details on safety, efficacy and clinical trials, and terminated trial analysis. The report also includes company profiles that highlight the cardiovascular drugs of different companies.

Cardiovascular disorders represent a collective group of disorders that affect the functioning of the heart and the blood vessels. These disorders are one the most prevalent groups of disorders in the world today, and represent a significant proportion of the world’s total diseased population. Most of them cause significant morbidity and disability.

The global cardiovascular therapeutics market was valued at $93.5 billion in 2010 and expected to reach revenues of $115.6 billion by 2017 with a CAGR of 3.1%. Approximately 127 million patients received pharmacological treatment for their cardiovascular diseases in 2011 with average cost of therapy being $596 per year. In addition, the average annual cost of therapy for the cardiovascular diseases therapeutic area appears likely to increase at a gradual rate over the next one to two years, with an expected price decline in 2011 onwards.

This report details the endpoints in clinical trials for cardiovascular disorders, highlighting the five major cardiovascular disorders, which are atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism. The classification of five major cardiovascular diseases is done on the basis of the number of pipeline molecules present in Phase III of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, such as those related to the effectiveness of treatment as well as other factors. However, endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be important to the objective of the study and represent the most effective way to assess pharmacological response.

Scope

- Data and analysis on the marketed products and analysis of their efficacy and safety details.
- Analysis of the five major cardiovascular diseases which include atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
- Analysis on most promising molecules of five major cardiovascular diseases with emphasis on their efficacy and safety details.
- Company profiling talks in detail about the companies, which are strong in the market.

Reasons to buy

- Understand the trends in clinical trial endpoints used for cardiovascular diseases
- Build effective strategies to launch their pipeline products by identifying the right endpoints
- Understand and apply surrogate endpoints and clinical biomarkers as endpoints for cardiovascular diseases
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.

1.1 List of Tables 5
1.2 List of Figures 7
2 Endpoints - Clinical Trials In Cardiovascular Disorders - Overview 10
2.1 Introduction 10
2.2 Types of Endpoints 10
2.2.1 Primary Endpoints 10
2.2.2 Secondary Endpoints 10
2.3 GBI Research Report Guidance 11
3 Endpoints - Clinical Trials In Cardiovascular Disorders - Major Endpoints of Top Five Cardiovascular Disorders 12
3.1 Endpoints - Major Marketed Drugs of Top Five Cardiovascular Disorders and their Regulatory Approval 12
3.1.1 Atherosclerosis 13
3.1.2 Atrial Fibrillation 13
3.1.3 Dyslipidemia 13
3.1.4 Hypertension 14
3.1.5 Venous Thromboembolism 14
4 Endpoints - Clinical Trials In Cardiovascular Disorders - Marketed and Pipeline Product Assessment 15
4.1 Atherosclerosis 15
4.1.1 Primary Endpoints Used in Atherosclerosis Clinical Trials 17
4.1.2 Secondary Endpoints Used in Atherosclerosis Clinical Trials 17
4.1.3 Major Marketed Drugs - Safety and Efficacy Analysis 17
4.1.4 Phase III Clinical Trial Analysis 21
4.1.5 Most Promising Drug’s Profile 27
4.1.6 Phase II Clinical Trial Analysis 31
4.1.7 Terminated Trials Analysis 35
4.2 Atrial Fibrillation 36
4.2.1 Primary Endpoints Used in Atrial Fibrillation 37
4.2.2 Secondary Endpoints Used in Atrial Fibrillation 37
4.2.3 Major Marketed Drugs - Safety and Efficacy Analysis 38
4.2.4 Phase III Clinical Trial Analysis 43
4.2.5 Most Promising Drug’s Profile 51
4.2.6 Phase II Clinical Trial Analysis 54
4.2.7 Terminated Trials Analysis 60
4.3 Dyslipidemia 61
4.3.1 Primary Endpoints Used in Dyslipidemia 61
4.3.2 Secondary Endpoints Used in Dyslipidemia 62
4.3.3 Major Marketed Drugs - Safety and Efficacy Analysis 62
4.3.4 Phase III Clinical Trial Analysis 69
4.3.5 Most Promising Drug’s Profile 76
4.3.6 Phase II Clinical Trial Analysis 81
4.3.7 Terminated Trials Analysis 87
4.4 Hypertension 88
4.4.1 Primary Endpoints Used in Hypertension 88
4.4.2 Secondary Endpoints Used in Hypertension 89
4.4.3 Major Marketed Drugs - Safety and Efficacy Analysis 89
4.4.4 Phase III Clinical Trial Analysis 94
4.4.5 Most Promising Drug’s Profile 108
4.4.6 Phase II Clinical Trial Analysis 110
4.4.7 Terminated Trials Analysis 117
4.5 Venous Thromboembolism 118
4.5.1 Primary Endpoints Used in Venous Thromboembolism 118
4.5.2 Secondary Endpoints Used in Venous Thromboembolism 119
4.5.3 Major Marketed Drugs - Safety and Efficacy Analysis 119
4.5.4 Phase III Clinical Trial Analysis 122
4.5.5 Most Promising Drug’s Profile 129
4.5.6 Phase II Clinical Trial Analysis 131
4.5.7 Terminated Trials Analysis 135
5 Endpoints - Clinical Trials In Cardiovascular Disorders - Competitive Landscape 136
5.1 Pfizer Inc. 136
5.1.1 Company Overview 136
5.1.2 Major Cardiovascular Drugs Marketed by Pfizer 136
5.2 Sanofi S.A. 138
5.2.1 Company Overview 138
5.2.2 Major Cardiovascular Drugs Marketed by Sanofi S.A. 138
5.3 Novartis AG 139
5.3.1 Company Overview 139
5.3.2 Major Cardiovascular Drugs Marketed by Novartis AG 139
5.4 AstraZeneca PLC 141
5.4.1 Company Overview 141
5.4.2 Major Cardiovascular Drugs Marketed by AstraZeneca PLC 141
5.5 Boehringer Ingelheim GmbH 142
5.5.1 Company Overview 142
5.5.2 Major Cardiovascular Drugs Marketed by Boehringer Ingelheim GmbH 142
5.6 Actelion Ltd. 143
5.6.1 Company Overview 143
5.6.2 Major Cardiovascular Drugs Marketed by Actelion Ltd. 143
5.7 Daiichi Sankyo Company Ltd. 144
5.7.1 Company Overview 144
5.7.2 Major Cardiovascular Drugs Marketed by Daiichi Sankyo Company Ltd. 144
5.8 Abbott Laboratories 145
5.8.1 Company Overview 145
5.8.2 Major Cardiovascular Drugs Marketed by Abbott Laboratories 145
5.9 Bayer AG 146
5.9.1 Company Overview 146
5.9.2 Major Cardiovascular Drugs Marketed by Bayer AG 146
5.10 GlaxoSmithKline PLC 147
5.10.1 Company Overview 147
5.10.2 Major Cardiovascular Drugs Marketed by GlaxoSmithKline PLC 147
6 Endpoints - Clinical Trials In Cardiovascular Disorders - Appendix 148
6.1 Market Definitions 148
6.2 Abbreviations 148
6.3 Research Methodology 149
6.3.1 Coverage 149
6.3.2 Secondary Research 150
6.3.3 Primary Research 150
6.3.4 Section Methodology 150
6.3.5 Expert Panel Validation 151
6.4 Contact Us 152
6.5 Disclaimer 152
6.6 Sources 152

1.1 List of Tables

Table 1: Endpoints - Clinical Trials in Cardiovascular Disorders, Number of Pipeline Products in Phase III Stage of Development, 2011 12
Table 2: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Endpoints for Major Marketed Drugs, 1990-2010 13
Table 3: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Endpoints for Major Marketed Drugs, 1990-2010 13
Table 4: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Endpoints for Major Marketed Drugs, 1990- 2010 14
Table 5: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Endpoints for Major Marketed Drugs, 1990- 2010 14
Table 6: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Trial Molecules, 2000-2010 24
Table 7: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Trial Molecules, 2000-2010 27
Table 8: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Trial Molecules, 2000-2010 33
Table 9: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase II Trial Molecules, 2000-2010 35
Table 10: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Terminated Trial Molecules, 2000-2010 35
Table 11: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Trial Molecules, 2000-2010 46
Table 12: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Trial Molecules, 2000-2010 50
Table 13: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Trial Molecules, 2000-2010 57
Table 14: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase II Trial Molecules, 2000-2010 60
Table 15: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Terminated Trial Molecules, 2000-2010 60
Table 16: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Trial Molecules, 2000-2010 72
Table 17: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase III Trial Molecules, 2000-2010 76
Table 18: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Trial Molecules, 2000-2010 84
Table 19: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Trial Molecules, 2000-2010 87
Table 20: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Terminated Trial Molecules, 2000-2010 87
Table 21: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Completed Phase III Trial Molecules, Global, 2000-2010 96
Table 22: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Trial Molecules, 2000-2010 107
Table 23: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Trial Molecules, 2000-2010 113
Table 24: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010 115
Table 25: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase II Trial Molecules, 2000-2010 116
Table 26: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Terminated Trial Molecules, 2000-2010 117
Table 27: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Trial Molecules, 2000-2010 125
Table 28: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Trial Molecules, 2000-2010 129
Table 29: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Trial Molecules, Global, 2000-2010 133
Table 30: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Ongoing Phase II Clinical Trials, Primary Endpoints, Global, 2000-2010 134
Table 31: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Ongoing Phase II Trial Molecules, Global, 2000-2010 134
Table 32: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Terminated Trial Molecules, Global, 2000-2010 135
Table 33: Endpoints - Clinical Trials in Cardiovascular Disorders, Pfizer Inc., Major Cardiovascular Drugs, 2010 136
Table 34: Endpoints - Clinical Trials in Cardiovascular Disorders, Sanofi S.A., Major Cardiovascular Drugs, 2010 138
Table 35: Endpoints - Clinical Trials in Cardiovascular Disorders, Novartis AG, Major Cardiovascular Drugs, 2010 139
Table 36: Endpoints - Clinical Trials in Cardiovascular Disorders, AstraZeneca Plc, Major Cardiovascular Drugs, 2010 141
Table 37: Endpoints - Clinical Trials in Cardiovascular Disorders Boehringer Ingelheim GmbH, Major Cardiovascular Drugs, 2010 142
Table 38: Endpoints - Clinical Trials in Cardiovascular Disorders, Actelion Inc., Major Cardiovascular Drugs, 2010 143
Table 39: Endpoints - Clinical Trials in Cardiovascular Disorders, Daiichi Sankyo Company Ltd., Major Cardiovascular Drugs, 2010 144
Table 40: Endpoints - Clinical Trials in Cardiovascular Disorders, Abbott Laboratories, Major Cardiovascular Drugs, 2010 145
Table 41: Endpoints - Clinical Trials in Cardiovascular Disorders, Bayer AG, Major Cardiovascular Drugs, 2010 146
Table 42: Endpoints - Clinical Trials in Cardiovascular Disorders, GlaxoSmithKline PLC, Major Cardiovascular Drugs, 2010 147

1.2 List of Figures

Figure 1: Endpoints - Clinical Trials in Cardiovascular Disorders, Number of Pipeline Products in Phase III Stage of Development, 2011 12
Figure 2: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010 21
Figure 3: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints,
2000-2010 22
Figure 4: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010 23
Figure 5: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 23
Figure 6: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010 25
Figure 7: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010 26
Figure 8: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 26
Figure 9: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010 31
Figure 10: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Clinical Trials, Secondary Endpoints, 2000-2010 32
Figure 11: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 32
Figure 12: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010 34
Figure 13: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase II Clinical Trials, Secondary Endpoints, 2000-2010 35
Figure 14: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010 43
Figure 15: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints,
2000-2010 44
Figure 16: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010 45
Figure 17: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 45
Figure 18: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010 48
Figure 19: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010 49
Figure 20: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints,
2000-2010 49
Figure 21: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010 54
Figure 22: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints,
2000-2010 55
Figure 23: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Secondary Endpoints, 2000-2010 56
Figure 24: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints,
2000-2010 56
Figure 25: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010 59
Figure 26: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase II Clinical Trials, Secondary Endpoints, 2000-2010 59
Figure 27: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010 69
Figure 28: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010 70
Figure 29: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010 71
Figure 30: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 71
Figure 31: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010 74
Figure 32: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010 75
Figure 33: Endpoints - Clinical Trials in Cardiovascular Disorder, Dyslipidemia, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 75
Figure 34: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010 81
Figure 35: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010 82
Figure 36: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Completed Phase II Clinical Trials, Secondary Endpoints, Global, 2000-2010 83
Figure 37: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010 83
Figure 38: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010 85
Figure 39: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Clinical Trials, Secondary Endpoints, 2000-2010 86
Figure 40: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 86
Figure 41: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010 94
Figure 42: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010 94
Figure 43: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010 95
Figure 44: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 95
Figure 45: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010 105
Figure 46: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010 106
Figure 47: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 106
Figure 48: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010 110
Figure 49: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010 111
Figure 50: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Secondary Endpoints, 2000-2010 112
Figure 51: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 112
Figure 52: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 116
Figure 53: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010 122
Figure 54: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010 123
Figure 55: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010 124
Figure 56: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 124
Figure 57: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010 127
Figure 58: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010 128
Figure 59: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010 128
Figure 60: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Primary Endpoints, Global, 2000-2010 131
Figure 61: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, Global, 2000-2010 131
Figure 62: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Secondary Endpoints, Global, 2000-2010 132
Figure 63: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, Global, 2000-2010 132
Figure 64: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Ongoing Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, Global, 2000-2010 134

Companies Menstion

Pfizer Inc.
Sanofi S.A.
Novartis AG
AstraZeneca PLC
Boehringer Ingelheim GmbH
Actelion Ltd.
Daiichi Sankyo Company Ltd.
Abbott Laboratories
Bayer AG
GlaxoSmithKline PLC